Skip to main content

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Biosplice Therapeutics, Inc

Start Date

May 4, 2022

End Date

April 30, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Biosplice Therapeutics, Inc

Start Date

May 4, 2022

End Date

April 30, 2027